Case Report (n=1)
No
Acute kidney injury in patients taking direct oral anticoagulants like edoxaban should raise suspicion for anticoagulant-related nephropathy, which can be diagnosed via renal biopsy and managed by discontinuing the offending drug.
ARN should be considered in edoxaban-treated patients with AKI and hematuria; extends DOAC reports but remains hypothesis-generating.
76歳，男性．A診療所にて尿道損傷による肉眼的血尿を機に，アスピリンからエドキサバンへ内服変更された後，腎機能低下を認めた．当院にて腎生検を施行し，抗凝固薬関連腎症と診断した．抗凝固薬中止後，腎機能は2，3週間ほどで改善し，肉眼的血尿も消失した．直接作用型経口抗凝固薬（direct oral anticoagulants：DOACs）やワルファリン等抗凝固薬内服歴がある患者で急性腎障害が認められた場合は，原因として抗凝固薬関連腎症を念頭に置く必要がある．
No takes yet. Share an insight, caveat, or question.
Kiyotoshi et al. (2022) conducted a case report in Anticoagulant-related nephropathy (n=1). Edoxaban was evaluated on Development of acute kidney injury and macroscopic hematuria.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: